157 related articles for article (PubMed ID: 19941475)
1. Thrombin-activated receptors: promising targets for cancer therapy?
García-López MT; Gutiérrez-Rodríguez M; Herranz R
Curr Med Chem; 2010; 17(2):109-28. PubMed ID: 19941475
[TBL] [Abstract][Full Text] [Related]
2. G-protein-coupled receptors as signaling targets for antiplatelet therapy.
Smyth SS; Woulfe DS; Weitz JI; Gachet C; Conley PB; Goodman SG; Roe MT; Kuliopulos A; Moliterno DJ; French PA; Steinhubl SR; Becker RC;
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):449-57. PubMed ID: 19023091
[TBL] [Abstract][Full Text] [Related]
3. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
4. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Lee H; Sturgeon SA; Jackson SP; Hamilton JR
Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
[TBL] [Abstract][Full Text] [Related]
5. Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent.
Lee S
Arch Pharm Res; 2011 Apr; 34(4):515-7. PubMed ID: 21544715
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of glyco-peptides as anti-cancer agents targeting thrombin-protease activated receptor-1 interaction.
Chang YH; Wu JC; Yu HM; Hsu HT; Wu YT; Yu AL; Yu CT; Wong CH
Chem Commun (Camb); 2020 May; 56(43):5827-5830. PubMed ID: 32329494
[TBL] [Abstract][Full Text] [Related]
7. Non-peptidic small-molecule antagonists of the human platelet thrombin receptor PAR-1.
Selnick HG; Barrow JC; Nantermet PG; Connolly TM
Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):47-59. PubMed ID: 15317290
[TBL] [Abstract][Full Text] [Related]
8. Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.
Wojtukiewicz MZ; Hempel D; Sierko E; Tucker SC; Honn KV
Cancer Metastasis Rev; 2015 Dec; 34(4):775-96. PubMed ID: 26573921
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.
Tsopanoglou NE; Maragoudakis ME
Semin Thromb Hemost; 2007 Oct; 33(7):680-7. PubMed ID: 18000795
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1).
Maryanoff BE; Zhang HC; Andrade-Gordon P; Derian CK
Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):13-36. PubMed ID: 15317288
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets.
Navarro-Núñez L; Rivera J; Guerrero JA; Martínez C; Vicente V; Lozano ML
Br J Pharmacol; 2009 Nov; 158(6):1548-56. PubMed ID: 19814731
[TBL] [Abstract][Full Text] [Related]
12. Vascular PAR-1: activity and antagonism.
Lang NN; Guðmundsdóttir IJ; Newby DE
Cardiovasc Ther; 2011 Dec; 29(6):349-61. PubMed ID: 20528879
[TBL] [Abstract][Full Text] [Related]
13. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
[TBL] [Abstract][Full Text] [Related]
14. Thrombin and protease-activated receptors (PARs) in atherothrombosis.
Martorell L; Martínez-González J; Rodríguez C; Gentile M; Calvayrac O; Badimon L
Thromb Haemost; 2008 Feb; 99(2):305-15. PubMed ID: 18278179
[TBL] [Abstract][Full Text] [Related]
15. Peptide-derived protease-activated receptor-1 (PAR-1) antagonists.
Seiler SM; Bernatowicz MS
Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):1-11. PubMed ID: 15317287
[TBL] [Abstract][Full Text] [Related]
16. Challenges and promises of developing thrombin receptor antagonists.
Yang J; Xu K; Seiffert D
Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):162-70. PubMed ID: 20874673
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis.
Blackburn JS; Brinckerhoff CE
Am J Pathol; 2008 Dec; 173(6):1736-46. PubMed ID: 18988801
[TBL] [Abstract][Full Text] [Related]
18. Platelet protease-activated receptor antagonism in cardiovascular medicine.
Wiisanen ME; Moliterno DJ
Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
[TBL] [Abstract][Full Text] [Related]
19. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
20. Streptococcal SpeB cleaved PAR-1 suppresses ERK phosphorylation and blunts thrombin-induced platelet aggregation.
Ender M; Andreoni F; Zinkernagel AS; Schuepbach RA
PLoS One; 2013; 8(11):e81298. PubMed ID: 24278414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
